[1]GUO ZQ, WANG QY, QI XS, et al. Recommendations for the diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases (2017) [J]. J Clin Hepatol, 2017, 33 (12) :2275-2277. (in Chinese) 郭泽淇, 王倩怡, 祁兴顺, 等.《2017年美国肝病学会非酒精性脂肪性肝病诊疗指导》摘译[J].临床肝胆病杂志, 2017, 33 (12) :2275-2277.
|
[2] WANG ZL. A review of nonalcoholic fatty liver disease in children[J]. Health literature, 2017, 10:165. (in Chinese) 王泽兰.关于儿童非酒精性脂肪肝的综述[J].保健文汇, 2017, 10:165.
|
[3]NOBILI V, MANCO M, DEVITO R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease:A randomized, controlled trial[J]. Hepatology, 2008, 48 (1) :119-128.
|
[4]MACAVEI B, BABAN A, DUMITRASCU DL, et al. Psychological factors associated with NAFLD/NASH:A systematic review[J].Eur Rev Med Pharmacol Sci, 2016, 20 (24) :5081-5097.
|
[5]HAUFE S, ENGELI S, KAST P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocalofic diets on intrahepatic fat in overweight and obese human subjects[J].Hepatology, 2011, 53 (5) :1504-1514.
|
[6]BARATTA F, PASTORI D, POLIMENI L, et al. Adherence to mediterranean diet and non-alcoholic fatty liver disease:Effect on Insulin Resistance[J]. Am J Gastroenterol, 2017, 112 (12) :1832-1839.
|
[7]CAKIR M, AKBULUT UE, OKTEN A. Association between adherence to the mediterranean diet and presence of nonalcoholic fatty liver disease in children[J]. Child Obes, 2016, 12 (4) :279-285.
|
[8]KEATING SE, HACKETT DA, PARKER HM, et al. Effect of aerobic exercise training dose on liver fat and visceral adiposity[J]. J Hepatol, 2015, 63 (1) :174-182.
|
[9]DIRK J, van der WINDT DJ, SUD V, et al. The effects of physical exercise on fatty liver disease[J]. Gene expression, 2018, 18 (2) :89-101.
|
[10]JIA GY, HANG T, GAO L, et al. Effect of aerobic exercise and resistance exercise in improving non-alcoholic fatty liver disease:A randomized controlled trial[J]. Chin J Hepatol, 2018, 26 (1) :34-41. (in Chinese) 贾国瑜, 韩涛, 高磊, 等.有氧运动和抗阻运动改善非酒精性脂肪肝的随机对照研究[J].中华肝脏病杂志, 2018, 26 (1) :34-41.
|
[11]NOBILI V, MANCO M, CIAMPALINI P, et al. Metformin use in children with nonalcoholic fatty liver disease:An open-label, 24-month, observational pilot study[J]. Clin Ther, 2008, 30 (6) :1168-1176.
|
[12]MAURAS N, DELGIORNO C, HOSSAIN J, et al. Metformin use in children with obesity and normal glucose toleranceeffects on cardiovascular markers and intrahepatic fat[J]. J Pediatr Endocrinol Metab, 2012, 25 (1-2) :33-40.
|
[13]OZTURK ZA, KADAYIFCI A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease[J]. World J Hepatol, 2014, 6 (4) :199-206.
|
[14]LAVINE JE, SCHWIMMER JB, van NATTA ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J]. JAMA, 2011, 305 (16) :1659-1668.
|
[15]Group of Endocrinology, Genetics and Metabolism, Society of Pediatrics, Chinese Medical Association; Digestive Group, Society of Pediatrics, Chinese Medical Association; Adolescent Medical Professional Committee, Society of Pediatrics, Chinese Medical Association, et al. Expert consensus on diagnosis and treatment of nonalcoholic fatty liver disease in children[J]. Chin J Pract Pediatr, 2018, 33 (7) :487-492. (in Chinese) 中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会消化学组, 中华医学会儿科学分会青春期医学专业委员会, 等.儿童非酒精性脂肪肝病诊断与治疗专家共识[J].中国实用儿科杂志, 2018, 33 (7) :487-492.
|
[16]SANYAL AJ, CHALASANI N, KOWDLEY KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 363 (12) :1185-1186.
|
[17]VAJRO P, MANDATO C, FRANZESE A, et al. Vitamin E treatment in pediatric obesity-related liver disease:A randomized study[J]. J Pediatr Gastroenterol Nutr, 2004, 38 (1) :48-55.
|
[18]LAVINE JE. Vitamin E treatment of nonalcoholic steatohepatitis in children:A pilot study[J]. J Pediatr, 2000, 136 (6) :734-738
|
[19]ABNER EL, SCHMITT FA, MENDIONDO MS, et al. Vitamin E and all-cause mortality:A meta-analysis[J]. Curr Aging Sci, 2011, 4 (2) :158-170.
|
[20]LI YW, HU YH, ZHU TT, et al. Clinical efficacy of compound glycyr-rhizin tablets in the treamlent of children with nonalcoholie fatty fiver disease[J]. Chin J Pract Pediatr, 2017, 19 (5) :505-509. (in Chinese) 李毓雯, 胡毓华, 朱甜甜, 等.复方甘草酸苷片治疗儿童非酒精性脂肪性肝病疗效观察[J].中国实用儿科杂志, 2017, 19 (5) :505-509.
|
[21]Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association. Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J]. J Clin Hepatol, 2013, 29 (9) :652-655. (in Chinese) 中国医师协会脂肪性肝病专家委员会.脂肪性肝病诊疗规范化的专家建议[J].临床肝胆病杂志, 2013, 29 (9) :652-655.
|
[22]BARLOW SE, EXPERT C. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity:Summary report[J].Pediatrics, 2007, 120 (4) :164-192.
|
[23]ESLAMPARAST T, EGHTESAD S, et al. Probiotics and non alcoholic fatty liver disease[J]. Middle East J Dig Dis, 2013, 5 (3) :129-136.
|
[24]ALISI A, BEDOGNI G. Randomised clinical trial:The benefical effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2014, 39 (11) :1276-1285.
|
[25]VAJRO P, MANDATO C. Effects of Lactobacillus rhamnosus strain GG in prdiatric obesity-related liver disease[J]. J Pediatr Gastroenterol Nutr, 2011, 52 (6) :740-743.
|
[26]PIRGON O, CEKMEZ F, BILGIN H, et al. Low 25-hydroxyvitamin D level is associated with insulin sensitivity in obese adolescents with non-alcoholic fatty liver disease[J]. Obes Res Clin Pract, 2013, 7 (4) :275-283.
|
[27]EI-SHERBINY M, ELDOSOKY M, EI-SHAFEY M, et al. Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet[J].Chem-Biol Interact, 2018, 25 (288) :65-75.
|
[28]KELISHADI R, SALEK S, SALEK M, et al. Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome:A triple-masked controlled trial[J]. J Pediatr (Rio J) , 2014, 90 (1) :28-34.
|
[29]CAVALIER E, FACHW, SOUBERBIELLE JC. A randomised, double-blinded, placebo-controlled, parallel study of vitamin D3 supplementation with different schemes based on multiples of 25, 000IU doses[J]. Int J Endocrinol, 2013, 2013:327265.
|
[30]BOZIC M, GUZMN C, BENET M, et al. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis[J]. J Hepatol, 2016, 65 (4) :748-757.
|
[31]WEI GC, HE JY. Traditional Chinese medicine intervention to nonalcoholic fatty liver disease based on physique identi cation[J]. J Changchun Univ Chin Med, 2018, 34 (3) :518-521. (in Chinese) 魏功昌, 何瑾瑜.中医体质辨识治疗非酒精性脂肪性肝病[J].长春中医药大学学报, 2018, 34 (3) :518-521.
|
[32]CUI JJ, ZHAO WX. Professor zhao wenxia's experience in the treatment of non-alcoholic fatty liver disease[J]. Chin Med Modern Distance Educ of China, 2014, 12 (22) :26-27. (in Chinese) 崔健娇, 赵文霞.赵文霞教授治疗非酒精性脂肪性肝病经验总结[J].中国中医药现代远程教育, 2014, 12 (22) :26-27.
|
[33] SAI YT. Clinical observation of combined Chinese and Western medicine in the treatment of non-alcoholic fatty liver disease[J. Med Inf, 2012, 25 (1) :129-130. (in Chinese) 赛咏婷.中西医结合治疗非酒精性脂肪肝疗效观察[J].医学信息, 2012, 25 (1) :129-130.
|
[34]IMPRIALOS K, STAVROPOULOS K, BOULOUKOU S, et al.Current and potential future pharmacological approaches for non-alcoholic fatty liver disease[J]. Curr Vasc Pharmacol, 2018, 16 (3) :276-288.
|
[35]BOWER G, TOMA T, HARLING L, et al. Bariatric surgery and non-alcoholic fatty liver disease:A systematic review of liver biochemistry and histology[J]. Obes Surg, 2015, 25 (12) :2280-2289.
|
[36]DYSON J, DAY C. Treatment of non-alcoholic fatty liver disease[J]. Dig Dis, 2014, 32 (5) :597-604.
|
[37]NICKEL F, TAPKING C, BENNER L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up:Bari Scan study[J]. Obes Surg, 2018, 28 (5) :1342-1350.
|